Trial Profile
Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs CST 101 (Primary) ; Inbakicept
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Sponsors ImmunityBio
- 13 Aug 2020 Planned End Date changed from 1 Apr 2019 to 31 Dec 2020.
- 25 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Apr 2019.
- 19 Oct 2017 Status changed from recruiting to active, no longer recruiting.